JP2024520234A - Ｐｓｄ－９５阻害剤及びその使用 - Google Patents

Ｐｓｄ－９５阻害剤及びその使用 Download PDF

Info

Publication number
JP2024520234A
JP2024520234A JP2023569757A JP2023569757A JP2024520234A JP 2024520234 A JP2024520234 A JP 2024520234A JP 2023569757 A JP2023569757 A JP 2023569757A JP 2023569757 A JP2023569757 A JP 2023569757A JP 2024520234 A JP2024520234 A JP 2024520234A
Authority
JP
Japan
Prior art keywords
seq
cpp
compound
compound according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520234A5 (cg-RX-API-DMAC10.html
Inventor
セレイカイテ，ヴィタ
レインハード オットー ベック－バートリング，クリスチャン
ストロムガード，クリスチャン
Original Assignee
ユニバーシティ オブ コペンハーゲン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ コペンハーゲン filed Critical ユニバーシティ オブ コペンハーゲン
Publication of JP2024520234A publication Critical patent/JP2024520234A/ja
Publication of JP2024520234A5 publication Critical patent/JP2024520234A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023569757A 2021-05-12 2022-05-12 Ｐｓｄ－９５阻害剤及びその使用 Pending JP2024520234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173587 2021-05-12
EP21173587.3 2021-05-12
PCT/EP2022/062893 WO2022238530A1 (en) 2021-05-12 2022-05-12 Psd-95 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520234A true JP2024520234A (ja) 2024-05-23
JP2024520234A5 JP2024520234A5 (cg-RX-API-DMAC10.html) 2025-05-19

Family

ID=75914418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569757A Pending JP2024520234A (ja) 2021-05-12 2022-05-12 Ｐｓｄ－９５阻害剤及びその使用

Country Status (16)

Country Link
US (1) US20240245793A1 (cg-RX-API-DMAC10.html)
EP (1) EP4337673B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520234A (cg-RX-API-DMAC10.html)
KR (1) KR20240007140A (cg-RX-API-DMAC10.html)
CN (1) CN117295755A (cg-RX-API-DMAC10.html)
AU (1) AU2022274309A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021410A2 (cg-RX-API-DMAC10.html)
CA (1) CA3218073A1 (cg-RX-API-DMAC10.html)
ES (1) ES3040762T3 (cg-RX-API-DMAC10.html)
IL (1) IL307244A (cg-RX-API-DMAC10.html)
MX (1) MX2023013313A (cg-RX-API-DMAC10.html)
PL (1) PL4337673T3 (cg-RX-API-DMAC10.html)
SA (1) SA523451347B1 (cg-RX-API-DMAC10.html)
TW (1) TW202306965A (cg-RX-API-DMAC10.html)
WO (1) WO2022238530A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202308712B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706670A1 (en) * 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2025009503A1 (ja) * 2023-07-03 2025-01-09 メスキュージェナシス株式会社 細胞膜透過性を有するペプチドおよびそのスクリーニング方法
WO2025051130A1 (zh) * 2023-09-07 2025-03-13 湖南中晟全肽生物科技股份有限公司 作为神经保护剂的药用化合物及其应用
CN117164725B (zh) * 2023-09-07 2024-05-10 湖南中晟全肽生物科技股份有限公司 一种突触后密度蛋白-95抑制剂多肽

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2320927T3 (pl) 2008-07-09 2016-02-29 Univ Copenhagen Modyfikowane peptydy jako potencjalne inhibitory w reakcjach receptorów PSD 95 i NMD

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
WO2020083905A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Inhibitors of pick1 and uses thereof

Also Published As

Publication number Publication date
KR20240007140A (ko) 2024-01-16
IL307244A (en) 2023-11-01
CA3218073A1 (en) 2022-11-17
US20240245793A1 (en) 2024-07-25
TW202306965A (zh) 2023-02-16
BR112023021410A2 (pt) 2023-12-19
AU2022274309A1 (en) 2023-09-28
MX2023013313A (es) 2023-12-04
CN117295755A (zh) 2023-12-26
EP4337673B1 (en) 2025-07-09
SA523451347B1 (ar) 2024-08-27
AU2022274309A9 (en) 2024-01-25
EP4337673A1 (en) 2024-03-20
ZA202308712B (en) 2025-02-26
WO2022238530A1 (en) 2022-11-17
PL4337673T3 (pl) 2026-01-05
ES3040762T3 (en) 2025-11-04
EP4337673C0 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
EP4337673B1 (en) Psd-95 inhibitors and uses thereof
JP6480865B2 (ja) 新規なα４β７ペプチド二量体拮抗薬
JP5683951B2 (ja) 長期間作用性ペプチド類似体のための組成物
KR102046830B1 (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
KR102787208B1 (ko) α4β7 인테그린 티오에테르 펩티드 길항제
JP6633523B2 (ja) Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
JPH03118330A (ja) フイブリノーゲンレセプター拮抗剤
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
JPH03118331A (ja) 環状フイブリノーゲンレセプター拮抗薬
KR20020010928A (ko) 인테그린 αｖβ６의 억제제로서의 사이클릭 펩타이드유도체
JP2599947B2 (ja) ペプチド化合物
CA2937032C (en) Activated neurotensin molecules and the uses thereof
CN116157140A (zh) 具有肾酶促效剂活性的稳定胜肽
HK40108323B (en) Psd-95 inhibitors and uses thereof
HK40108323A (en) Psd-95 inhibitors and uses thereof
US20060275213A1 (en) Tumor targeting agents and uses thereof
WO2026058014A1 (en) Peptide conjugates comprising blood brain barrier penetrating oligopeptides for use in therapeutic and diagnostic methods
JP2024536413A (ja) 二環式ペプチドリガンド薬物コンジュゲート
CA3148347A1 (en) Methods of making incretin analogs
JPH0597699A (ja) プロペンアミド誘導体の重合物からなる癌転移抑制剤
HK1229227B (en) Fatty acid derivatives of dimeric inhibitors of psd-95
JPH0717999A (ja) ペプチド誘導体及びその用途
JPH06228189A (ja) ペプチド誘導体およびその用途
JPH0770183A (ja) ペプチド誘導体及びその用途

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20231109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616